DCVC's Pharmaceutical Portfolio

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Computational Drug Discovery for Small-Molecule Teams

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.

Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients.

Superfluid Dx is a biotechnology company developing novel blood-based early detection.

A clinical stage drug development company who aims to invent novel drugs for hard-to-treat diseases using its proprietary AI platform

X-37 is a pharmaceutical discovery and development company

Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics.

HealthMode delivers AI-enabled digital measurement methods to increase the precision and speed of clinical research, and improve healthcare.

Capella Bioscience engages in the discovery and development of monoclonal antibodies.